



TN 03/2021: Trader Notice on update from Commission on treatment requirements for dairy products in shelf-stable composite products

Update

Shelf-stable composite products that do not contain meat (excluding gelatine, collagen and highly refined products) will require to be accompanied by a private attestation from April 21st 2021. Point 10 of the private attestation requires that any dairy products contained in the composite product have been subjected to a treatment at least equivalent to the risk-mitigating treatments in Annex XXVII of [Regulation \(EU\) 2020/692](#).

Point 10:

Contain dairy products which have undergone a specific risk-mitigating treatment at least equivalent to one of the treatments provided for in column B of the table set out in Annex XXVII to Commission Delegated Regulation (EU) 2020/692¹⁽⁴⁾;

The Commission have agreed that it would be disproportionate to require such strict risk-mitigating treatments to dairy products that originate from countries that are already authorised for the entry into the Union of raw milk or dairy products

[Regulation \(EU\) 2020/692](#) will be amended to allow the shelf-stable composite products containing dairy products that have been pasteurised, as long as the country of origin is listed for the import of raw milk and pasteurised milk.

This means that shelf-stable composite products containing pasteurised milk products will be permitted to be imported from GB accompanied by a private attestation.

Interim Measures

As this amendment will not be adopted by April 21st, the following interim measures will apply. These are as follows (depending on the country of origin of the product and the dairy component of that product);

1. If the country of origin of the composite product (as indicated in box 1.7 of Part I of the attestation) and the country of origin of the milk/dairy product (i.e. country where the approved establishment of origin is) are listed either in;
 - i. column A and B of the table set out in Annex I to [Regulation \(EU\) No 605/2010](#)
 - or
 - ii. Annex XVII to [Implementing Regulation \(EU\) 2021/404](#)

➔ **Point 10 of Part II of the attestation may be deleted**



2. If the country of origin of the composite product (as indicated in box 1.7 of Part I of the attestation) and the country where of origin of the milk/dairy product (i.e. country where the approved establishment of origin is) are listed in;
 - i. column C of the table set out in Annex I to [Regulation \(EU\) No 605/2010](#) or
 - ii. Annex XVIII to [Implementing Regulation \(EU\) 2021/404](#)

➔ **Reference to Column B in point 10 can be changed to Column A**

Revised Point 10:

Contain dairy products which have undergone a specific risk-mitigating treatment at least equivalent to one of the treatments **provided for in column A of the table set out in Annex XXVII** to Commission Delegated Regulation (EU) 2020/692¹⁽⁴⁾;

3. If shelf-stable composite products containing dairy products are imported from a third country which is not listed for the import of dairy into the Union then the content of point 10 must be kept as is – i.e. those dairy products contained in the composite product must have been subjected to a treatment equivalent to UHT or sterilisation.

Further Information:

Further information is available on the Commission's website at the following link: [Commission guidance on Composite Products](#) or at [gov.ie - Importing Composite Products \(www.gov.ie\)](#)